Previous 10 | Next 10 |
Study for hospitalized moderate to severe cases in Kuwait terminated, while study for out-patient mild to moderate cases continues in North America Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries to...
Dr. Reddy’s Laboratories ([[RDY]] -1.7%) says that the Drugs Control General of India ((DCGI)) has given it the go-ahead to conduct phase 3 clinical trial for the Sputnik V COVID-19 vaccine in India, a day ahead of the scheduled mass vaccination drive in the country...
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India. The phase 3 study of Sputni...
Dr. Reddy’s submitted the phase 2 safety data for DCGI’s approval to continue phase 3 clinical trials Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has re...
Dr. Reddy's Laboratories (RDY) announces the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the FDA, for the treatment of hyperuricemia (elevated levels of uric acid in the blood) associated with goutwith cardi...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Feb...
Earnings call slated for January 29 th @ 5:30 PM IST / 7:00 AM EST Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the third quarter ended December 31, 2020 on Friday, January 29 th , 2021 after the Boa...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), Appili Therapeutics (TSX: APLI, OTCQX: APLIF) and Global Response Aid FZCO (GRA) today announced that Dr. Reddy...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY referred to as “Dr. Reddy’s”) today announced the secondary listing of its American Depository Receipts (ADRs) on NSE IFSC Limited under the symbol ’DRREDDY’ on December 9, 2020...
Exelixis ([[EXEL]] +1.6%) exercises its option for Aurigene's CDK7 inhibitor, now known as XL102, and submits an Investigational New Drug Application to the U.S. Food and Drug Administration to evaluate XL102 alone or in combination therapy for treatment of inoperable locally advanced or meta...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...